KIT as a Therapeutic Target in Metastatic Melanoma
2011; American Medical Association; Volume: 305; Issue: 22 Linguagem: Inglês
10.1001/jama.2011.746
ISSN1538-3598
Autores Tópico(s)Gastrointestinal Tumor Research and Treatment
Resumogreatest morbidity and mortality of all skin cancers. 1 An estimated 68 130 invasive melanomas were diagnosed and 8700 deaths due to metastatic disease were recorded in the United States in 2010. 2 Dacarbazine, 3 interleukin 2, 4 and ipilimumab are approved for the treatment of metastatic melanoma by the US Food and Drug Administration.][5] Melanoma is composed of several biologically distinct subtypes, each with unique genetic and clinical features, 6 and each likely to respond differently to any one therapeutic strategy.The most common melanoma subtype in the United States arises from non-chronically sun-damaged (non-CSD) skin and often harbors activating mutations in BRAF. 7elanoma arising from mucosal, acral,
Referência(s)